Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SCN4A | P35499 | 2/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116986 | 0.87 | NPC1 (0.68) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9776980 | 0.85 | DYRK1A (0.70) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL18154477 | 0.85 | DYRK1A (0.81) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL18154178 | 0.83 | DYRK1A (0.79) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28878452 | 0.83 | DYRK1A (0.67) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL19850784 | 0.83 | DYRK1A (0.67) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL29975006 | 0.83 | DYRK1A (0.67) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL23104940 | 0.82 | DYRK1A (1.00) | DYRK1ANPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL6193159 | 0.82 | DYRK1A (0.77) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21568256 | 0.82 | DYRK1A (0.77) | DYRK1ANPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0788491-B1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | RHONE POULENC RORER SA (FR) | 1999-12-01 | — | — | EP | claimed |
| US-5795903-A | 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives | RHONE-POULENC RORER S.A. (FR) | 1998-08-18 | — | — | US | claimed |
| EP-0788491-A1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | Aventis Pharma S.A. (FR) | 1997-08-13 | — | — | EP | claimed |
| WO-1996013492-A1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1996-05-09 | — | — | WO | claimed |
| US-20260014123-A1 | USE OF RILUZOLE ORAL DISINTEGRATING TABLETS FOR TREATING DISEASES | BIOHAVEN THERAPEUTICS LTD (US) | 2026-01-15 | — | — | US | disclosed |
| US-20200262784-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-08-20 | — | — | US | disclosed |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170298008-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-10-19 | — | — | US | disclosed |
| EP-0788491-B1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | RHONE POULENC RORER SA (FR) | 1999-12-01 | — | — | EP | disclosed |
| US-5795903-A | 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives | RHONE-POULENC RORER S.A. (FR) | 1998-08-18 | — | — | US | disclosed |
| EP-0788491-A1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | Aventis Pharma S.A. (FR) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013492-A1 | 6-POLYFLUOROALKOXY AND 6-POLYFLUOROALKYL-2-AMINOBENZOTHIAZOLE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, ARSA, ALK | DYRK1A 2630/4885NPC1 223/4885RAB9A 1460/4885 |
| US-20260014123-A1 | USE OF RILUZOLE ORAL DISINTEGRATING TABLETS FOR TREATING DISEASES | SORD, IL2, CHIT1 | DYRK1A 1094/4885NPC1 982/4885RAB9A 176/4885 |
| US-20170298008-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, ARSA, ALK | DYRK1A 2776/4885NPC1 222/4885RAB9A 1242/4885 |
| US-20200262784-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, AFF2, AFF4 | DYRK1A 2491/4885NPC1 217/4885RAB9A 1219/4885 |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | AHR, AFF2, AFF4 | DYRK1A 2510/4885NPC1 216/4885RAB9A 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.